Validation of the revised International Prognostic Scoring System (IPSS-R) in patients with myelodysplastic syndrome: A multicenter study

IPSS‐R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk‐stratify the patients

“…In this study, we applied the IPSS-R to 555 patients with primary MDS in Taiwan. Compared with the previous reports, [4][5][6] fewer cases were in very low-and low-risk groups in this study (3.1% vs. 14-38% and 22.9% vs. 32-38%, respectively). In contrast, about one half of patients had high or very high-risk MDS in our cohort, compared with only 23-39% in the West [4][5][6].…”

“…Actually, our cohort consisted of low percentage of patients with RARS as well as those with very good cytogenetic changes. Neukirchen et al [6] also found the IPSS-R was not able to discriminate significantly the OS between very low and low risk groups.…”

“…Compared with IPSS, the IPSS-R split patients with fewer than 5% BM blast into those with 0%-2% and greater than 2% to fewer than 5%, incorporated more sophisticated cytogenetic classification to separate patients into five, rather than three risk subtypes, and scored the depth of cytopenias to improve prognosis assessment for primary MDS patients [4]. It has been shown that IPSS-R predicts survival and leukemic evolution in MDS patients significantly better than IPSS in Western countries [5][6][7][8]. Since the demographics and disease natures in MDS patients are different between Asian and Western countries [9][10][11][12], it is unclear whether this new risk model is similarly useful for risk stratification of MDS in Asia.…”

Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group

“…The design of the cytogenetic module of the IPSS/-R is based on chromosome banding analysis of bone marrow metaphases of primary untreated newly diagnosed MDS patients only, 3,7 but several groups have already demonstrated the successful application of the IPSS and IPSS-R in treated and in secondary therapy-related MDS patients. [18][19][20][21][22] Here, we were able to show that, in our cohort, there was no significant difference in OS and AML-free survival between treated and untreated patients. OS and AML-free survival were shorter in treated patients, reflecting the fact that the treated group contained more patients with poor prognosis that needed specific treatment regimens.…”

Clinical and genetic predictors of prognosis in myelodysplastic syndromes

“…For example, the IPSS-R has been validated at times other than diagnosis, in patients treated with lenalidomide, in patients treated with hypomethylating agents, and in patients receiving a stem cell transplant. [9][10][11][12][13] It is important to note that while the IPSS-R can risk stratify patients in these scenarios, the median survival estimates published with the IPSS-R may not be accurate in these contexts. Validation studies comparing prognostic models suggest that the IPSS-R appears to outperform the IPSS and WPSS in these broader contexts.…”